TABLE V. Clinical and molecular description by case of the hepatitis B virus (HBV)-infected Mexican children with clinical hepatitis from 2005-2009.

Case	Age	Sex	ALT (UI/L)	DB (mg/dL)	ALF	Hepatitis B vaccinea [doses (n)]	Anti-HAV IgM	HBsAg	Anti-HBc total	Anti-HBc IgM	HBV genotype
1	10	M	328	1.6	No	3	-	+	-	-	H
2	5	F	224	0.4	No	3	+	+	-	-	NG
3	6	M	689	4.3	No	3	-	+	-	-	NG
4	2	M	88	0.3	No	3	-	-	+	-	H
5	4	F	629	1.4	No	3	+	-	-	+	H
6	2	F	205	3.9	No	3	+	-	-	-	H
7	3	F	1,982	3.2	No	3	+	-	-	-	H
8	4	M	680	4.1	No	3	+	-	-	-	H
9	6	F	1,041	3.2	No	0	-	-	-	-	H
10	6	M	210	3.5	No	0	-	-	-	-	H
11	7	F	334	2.9	No	0	+	-	-	-	H
12	7	M	2,877	12.3	No	0	-	-	-	-	H
13	7	M	3,389	4.4	No	0	+	-	-	-	H
14	8	M	1,110	1.7	No	0	+	-	-	-	H
15	11	M	171	1.3	No	0	+	-	-	-	H
16	11	F	74	1.8	No	0	+	-	-	-	H
17	14	F	76	5.2	No	0	-	-	-	-	H
18	14	M	220	0.8	No	0	+	-	-	-	H
19	15	F	664	1.1	No	0	+	-	-	-	H
20	5	M	620	2.9	No	0	+	-	-	-	NG
21	5	M	107	0.7	No	0	-	-	-	-	NG
22	1	F	25,823	11.0	Yes	0	-	-	-	-	G
23	9	M	805	0.4	No	0	-	-	-	-	G
24	2	F	913	8.1	No	3	-	-	-	-	A

a: a child with a complete three-dose schedule at two, four and six months of age; ALF: acute liver failure; ALT: alanine aminotransferase; DB: direct bilirubin; F: female; HAV: hepatitis A virus; HBc: hepatitis B core antibody; HBsAg: hepatitis B surface antigen; M: male; NG: non-typeable genotype as defined in Table II.